Patents Assigned to Sequoia Pharmaceuticals
-
Patent number: 9849107Abstract: Methods of inhibiting cytochrome P450 enzymes are provided that can be used for improving the treatment of diseases by preventing degradation of drugs or other molecules by cytochrome P450. Pharmaceutical compositions are provided that can act as boosters to improve the pharmacokinetics, enhance the bioavailability, and enhance the therapeutic effect of drugs that undergo in vivo degradation by cytochrome P450 enzymes.Type: GrantFiled: January 11, 2016Date of Patent: December 26, 2017Assignee: SEQUOIA PHARMACEUTICALS, INC.Inventors: Michael Eissenstat, Dehui Duan
-
Patent number: 9604952Abstract: Methods of inhibiting cytochrome P450 2D6 enzymes are provided that can be used for improving the treatment of diseases by preventing degradation of drugs or other molecules by cytochrome P450 2D6. Pharmaceutical compositions are provided that can act as boosters to improve the pharmacokinetics, enhance the bioavailability, and enhance the therapeutic effect of drugs that undergo in vivo degradation by cytochrome P450 2D6 enzymes.Type: GrantFiled: July 29, 2014Date of Patent: March 28, 2017Assignee: Sequoia Pharmaceuticals, Inc.Inventors: Michael Eissenstat, Dehui Duan, Ji-Hye Kang
-
Patent number: 9540354Abstract: Methods of inhibiting cytochrome P450 enzymes are provided that can be used for improving the treatment of diseases by preventing degradation of drugs or other molecules by cytochrome P450. Pharmaceutical compositions are provided that can act as boosters to improve the pharmacokinetics, enhance the bioavailability, and enhance the therapeutic effect of drugs that undergo in vivo degradation by cytochrome P450 enzymes.Type: GrantFiled: December 9, 2014Date of Patent: January 10, 2017Assignee: SEQUOIA PHARMACEUTICALS, INC.Inventors: Michael Eissenstat, Dehui Duan
-
Patent number: 9403789Abstract: Benzofuran-containing amino acid compounds are provided that are potent inhibitors of cytochrome P450 (CYP) enzymes. The compounds have the general structure where at least one of R1, R2, R3, R4, R5, and R6 is —S(O)n—(CH2)0-3-(benzofuranyl), —(CH2)1-5—N(R)(—SO2-benzofuranyl), —C(O)n—(CH2)0-3-(benzofuranyl), —(CH2)1-5—N(R)(C(?O)-(benzofuranyl), or C1-C6 alkylene-(benzofuranyl). Pharmaceutical compositions containing the inhibitors are provided and these compositions can act as boosters to improve the pharmacokinetics, enhance the bioavailability, and enhance the therapeutic effect of drugs that undergo in vivo degradation by cytochrome P450 enzymes.Type: GrantFiled: February 23, 2009Date of Patent: August 2, 2016Assignee: SEQUOIA PHARMACEUTICALS, INC.Inventors: Michael Eissenstat, Dehui Duan, Jihye Kang
-
Patent number: 9233952Abstract: Methods of inhibiting cytochrome P450 enzymes are provided that can be used for improving the treatment of diseases by preventing degradation of drugs or other molecules by cytochrome P450. Pharmaceutical compositions are provided that can act as boosters to improve the pharmacokinetics, enhance the bioavailability, and enhance the therapeutic effect of drugs that undergo in vivo degradation by cytochrome P450 enzymes.Type: GrantFiled: July 9, 2013Date of Patent: January 12, 2016Assignee: Sequoia Pharmaceuticals, Inc.Inventors: Michael Eissenstat, Dehui Duan
-
Patent number: 8952056Abstract: Methods of inhibiting cytochrome P450 enzymes are provided that can be used for improving the treatment of diseases by preventing degradation of drugs or other molecules by cytochrome P450. Pharmaceutical compositions are provided that can act as boosters to improve the pharmacokinetics, enhance the bioavailability, and enhance the therapeutic effect of drugs that undergo in vivo degradation by cytochrome P450 enzymes.Type: GrantFiled: February 23, 2009Date of Patent: February 10, 2015Assignee: Sequoia Pharmaceuticals, Inc.Inventors: Michael Eissenstat, Dehui Duan, Sergi Gulnik, John W. Erickson
-
Patent number: 8906647Abstract: Methods of inhibiting cytochrome P450 enzymes are provided that can be used for improving the treatment of diseases by preventing degradation of drugs or other molecules by cytochrome P450. Pharmaceutical compositions are provided that can act as boosters to improve the pharmacokinetics, enhance the bioavailability, and enhance the therapeutic effect of drugs that undergo in vivo degradation by cytochrome P450 enzymes.Type: GrantFiled: February 23, 2009Date of Patent: December 9, 2014Assignee: Sequoia Pharmaceuticals, Inc.Inventors: Michael Eissenstat, Dehui Duan
-
Patent number: 8791157Abstract: Methods of inhibiting cytochrome P450 2D6 enzymes are provided that can be used for improving the treatment of diseases by preventing degradation of drugs or other molecules by cytochrome P450 2D6. Pharmaceutical compositions are provided that can act as boosters to improve the pharmacokinetics, enhance the bioavailability, and enhance the therapeutic effect of drugs that undergo in vivo degradation by cytochrome P450 2D6 enzymes.Type: GrantFiled: April 1, 2013Date of Patent: July 29, 2014Assignee: Sequoia Pharmaceuticals, Inc.Inventors: Michael Eissenstat, Dehui Duan, Ji-Hye Kang
-
Patent number: 8703700Abstract: Inhibitors of the hepatitis C virus (HCV) NS3 protease are provided. In particular, bimacrocyclic compounds and their pharmaceutical compositions for the treatment of HCV infections are provided. Methods of making the bimacrocyclic compounds and their pharmaceutical compositions, and methods of using the compounds for treating HCV infections are also provided.Type: GrantFiled: May 24, 2010Date of Patent: April 22, 2014Assignee: Sequoia Pharmaceuticals, Inc.Inventors: Pavel Majer, Michael Eissenstat, Rongjuan Lu
-
Patent number: 8673970Abstract: Compositions and methods of treating viral infections are provided. More particularly, compositions including a combination of protease inhibitors and cytochrome p450 enzyme inhibitors are provided. Methods of using the compositions for treatment of diseases or disorders caused by a virus such as HIV infections are also provided.Type: GrantFiled: February 23, 2009Date of Patent: March 18, 2014Assignee: Sequoia Pharmaceuticals, Inc.Inventors: Michael Eissenstat, Dehui Duan, John W. Erickson
-
Patent number: 8569364Abstract: Methods of inhibiting cytochrome P450 2D6 enzymes are provided that can be used for improving the treatment of diseases by preventing degradation of drugs or other molecules by cytochrome P450 2D6. Pharmaceutical compositions are provided that can act as boosters to improve the pharmacokinetics, enhance the bioavailability, and enhance the therapeutic effect of drugs that undergo in vivo degradation by cytochrome P450 2D6 enzymes.Type: GrantFiled: November 26, 2008Date of Patent: October 29, 2013Assignee: Sequoia Pharmaceuticals, Inc.Inventors: Michael Eissenstat, Dehui Duan, Ji-Hye Kang
-
Patent number: 8481520Abstract: Methods of inhibiting cytochrome P450 enzymes are provided that can be used for improving the treatment of diseases by preventing degradation of drugs or other molecules by cytochrome P450. Pharmaceutical compositions are provided that can act as boosters to improve the pharmacokinetics, enhance the bioavailability, and enhance the therapeutic effect of drugs that undergo in vivo degradation by cytochrome P450 enzymes.Type: GrantFiled: November 1, 2011Date of Patent: July 9, 2013Assignee: Sequoia Pharmaceuticals, Inc.Inventors: Michael Eissenstat, Dehui Duan
-
Patent number: 8389571Abstract: Resistance-repellent and multidrug resistant retroviral protease inhibitors are provided. Pharmaceutical composition comprising such compounds, and methods of using such compounds to treat HIV infections in mammals, are also provided.Type: GrantFiled: July 19, 2011Date of Patent: March 5, 2013Assignee: Sequoia Pharmaceuticals, Inc.Inventor: Michael Eissenstat
-
Publication number: 20120141414Abstract: Inhibitors of the hepatitis C virus (HCV) NS3 protease are provided. In particular, bimacrocyclic compounds and their pharmaceutical compositions for the treatment of HCV infections are provided. Methods of making the bimacrocyclic compounds and their pharmaceutical compositions, and methods of using the compounds for treating HCV infections are also provided.Type: ApplicationFiled: May 24, 2010Publication date: June 7, 2012Applicant: Sequoia Pharmaceuticals, Inc.Inventors: Pavel Majer, Michael Eissenstat, Rongjuan Lu
-
Publication number: 20120053132Abstract: Methods of inhibiting cytochrome P450 enzymes are provided that can be used for improving the treatment of diseases by preventing degradation of drugs or other molecules by cytochrome P450. Pharmaceutical compositions are provided that can act as boosters to improve the pharmacokinetics, enhance the bioavailability, and enhance the therapeutic effect of drugs that undergo in vivo degradation by cytochrome P450 enzymes.Type: ApplicationFiled: November 1, 2011Publication date: March 1, 2012Applicant: Sequoia Pharmaceuticals, Inc.Inventors: Michael Eissenstat, Dehui Duan
-
Publication number: 20110281824Abstract: Resistance-repellent and multidrug resistant retroviral protease inhibitors are provided. Pharmaceutical composition comprising such compounds, and methods of using such compounds to treat HIV infections in mammals, are also provided.Type: ApplicationFiled: July 19, 2011Publication date: November 17, 2011Applicant: Sequoia Pharmaceuticals, Inc.Inventor: Michael EISSENSTAT
-
Patent number: 8048871Abstract: Methods of inhibiting cytochrome P450 enzymes are provided that can be used for improving the treatment of diseases by preventing degradation of drugs or other molecules by cytochrome P450. Pharmaceutical compositions are provided that can act as boosters to improve the pharmacokinetics, enhance the bioavailability, and enhance the therapeutic effect of drugs that undergo in vivo degradation by cytochrome P450 enzymes.Type: GrantFiled: August 20, 2007Date of Patent: November 1, 2011Assignee: Sequoia Pharmaceuticals, Inc.Inventors: Michael Eissenstat, Dehui Duan
-
Publication number: 20110182854Abstract: Novel compounds that are potent inhibitors of hepatitis C virus protease are provided. Pharmaceutical compositions containing one or more of these inhibitors, methods of preparing the inhibitors and methods of using the inhibitors to treat hepatitis C and related disorders also are provided.Type: ApplicationFiled: August 20, 2009Publication date: July 28, 2011Applicant: SEQUOIA PHARMACEUTICALS, INC.Inventors: Michael Eissenstat, Rongjian Lu, Sang Uk Kang
-
Patent number: 7981929Abstract: Resistance-repellent and multidrug resistant retroviral protease inhibitors are provided. Pharmaceutical composition comprising such compounds, and methods of using such compounds to treat HIV infections in mammals, are also provided.Type: GrantFiled: March 17, 2008Date of Patent: July 19, 2011Assignee: Sequoia Pharmaceuticals, Inc.Inventor: Michael Eissenstat
-
Publication number: 20110124578Abstract: Methods of inhibiting cytochrome P450 enzymes are provided that can be used for improving the treatment of diseases by preventing degradation of drugs or other molecules by cytochrome P450. Pharmaceutical compositions are provided that eases can act as boosters to improve the pharmacokinetics, enhance the bioavailability, and enhance the therapeutic effect of drugs that undergo in vivo degradation by cytochrome P450 enzymes.Type: ApplicationFiled: February 23, 2009Publication date: May 26, 2011Applicant: Sequoia Pharmaceuticals Inc.Inventors: Michael Eissenstat, Dehui Duan, Jihye Kang